Tags : Indivumed

PharmaShots Weekly Snapshot (January 20-24, 2020)

1. Epizyme’s Tazverik (tazemetostat) Receives the US FDA’s Accelerated Approval as the First Therapy for Epithelioid Sarcoma Published: Jan 23, 2020 | Tags: Epizyme, Tazverik, tazemetostat, Receives, US, FDA, Accelerated Approval, First Therapy, Epithelioid Sarcoma 2. Evarsana Signs an Agreement with Evoke Pharma to Commercialize Gimoti in the US Published: Jan 23, 2020 | Tags: Evarsana, Signs, […]Read More

Evotec and Indivumed Collaborate to Develop Therapies for Patients with

Shots: The companies enter into precision medicine collaboration to discover and develop first-in-class therapies to treat patients with NSCLC. The companies will share the development cost while Evotec will be responsible for partnering of the programs and the platform The agreement will merge Evotec’s bioinformatics analysis platform “PanHunter’’ and its small molecule & Ab discovery […]Read More

Evotec Signs a Research Agreement with Indivumed to Develop Precision

Shots: Indivumed to receive upfront from Evotec, for accessing Indivumed’s database “IndivuType” and both companies will jointly invest in data analysis, target identification, validation, and drug discovery. Evotec will be responsible for upcoming partnering for the program/platform The focus of the agreement is to develop precision therapies for CRC patients with the combination of Evotec’s […]Read More